Friday, June 12, 2026
← Back to archivePolicy
Policy•STAT News•Jun 11, 2026
An obesity drug deep-dive, and peptides move mainstream
background ▾
- •An obesity drug deep-dive, and peptides move mainstream
Policy•Fierce Pharma•Jun 12, 2026
Genentech executes another round of layoffs, with 3 VPs axed
background ▾
- •Three senior VPs departed Genentech as part of gRED restructuring, though total headcount impact remains undisclosed
GenentechRoche
→ Read original articlePolicy•Fierce Pharma•Jun 12, 2026
AI use is surging across HHS, jumping 148% at the FDA in 2025, Bipartisan Policy Center data finds
background ▾
- •FDA AI use jumped 148% in 2025 according to Bipartisan Policy Center data, signaling accelerated digital transformation in drug regulation
- •Reported growth may be inflated by new reporting requirements rather than actual new AI implementations, suggesting caution in interpreting headline numbers
- •Watch for clarity on which specific FDA functions (e.g., NDA review, safety monitoring, manufacturing inspections) are actually deploying AI and what measurable outcomes result
Policy•Fierce Pharma•Jun 12, 2026
Novo reports data breach, tells clinical trial patients to 'remain vigilant'
background ▾
- •Novo Nordisk data breach impacts clinical trial patients, raising questions about the company's data security protocols and potential regulatory consequences
- •Breach highlights biopharma industry's vulnerability to cyberattacks targeting both competitive IP and protected health information
- •Specific breach details, number of affected patients, and whether regulatory authorities have been notified remain publicly undisclosed
Novo Nordisk
→ Read original articlePolicy•Fierce Pharma•Jun 12, 2026
Joint initiative of 5 EU countries calls for 'unified approach' to pharma framework amid US drug pricing pressure
background ▾
- •Five EU nations are coordinating to develop a unified pharma pricing approach, signaling potential policy realignment in response to U.S. pricing dynamics.
- •The initiative suggests member states view fragmented EU pricing strategies as a competitive disadvantage in the global market.
Market Access
Market Access•Fierce Pharma•Jun 12, 2026
‘Not simply saving cost’: Inside Astellas CEO’s 5-year strategy to counter Xtandi’s patent cliff
background ▾
- •Xtandi faces a $6 billion patent cliff, representing a material threat to Astellas' revenue base and requiring significant strategic mitigation
- •The company is committing $1.3 billion to a cost-savings program integrated into a five-year strategic plan, indicating this is a central corporate priority rather than reactive cost control
- •Watch for details on whether this strategy includes pipeline advancement, geographic expansion, or life-cycle management initiatives to offset Xtandi's decline
AstellasXtandi
→ Read original articleMarket Access•Fierce Biotech•Jun 11, 2026
Cardiovascular-focused Kardigan plans to bring in cozy $320M haul from upcoming IPO
background ▾
- •Kardigan's IPO capitalizes on strong biotech market momentum and experienced cardiovascular leadership, but the company is pre-revenue with three programs still in mid-to-late phase 2 development
- •The lead program danicamtiv originated from MyoKardia's successful mavacamtiv/Camzyos ($1.07B in 2024 sales), providing some validation of the cardiac myosin modulation approach, though different mechanism
KardiganBristol Myers SquibbMyoKardiadanicamtivataciguattonlamarsen
→ Read original articleMarket Access•Fierce Pharma•Jun 12, 2026
Madrigal takes giant inflatable liver on US tour in disease awareness push
background ▾
- •Madrigal is investing in consumer-facing disease awareness marketing to build demand for fatty liver treatments
Madrigal Pharmaceuticals
→ Read original articleMarket Access•Fierce Pharma•Jun 12, 2026
Olixir NY teams with Crohn's & Colitis Foundation for ‘Spill Your Guts’ campaign
background ▾
- •Disease awareness campaign for IBD launched by patient foundation, not a pharma company
Market Access•Fierce Pharma•Jun 12, 2026
‘I’m a lot more optimistic today’: Mike Doustdar tells Fierce about pivotal first year as Novo Nordisk CEO
background ▾
- •New CEO signals confidence in Novo Nordisk's competitive transformation after first year in role
Novo Nordisk
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Jun 12, 2026
Novartis' phase 1/2 win tees up regulatory talks about dystrophy drug from $12B Avidity takeover
background ▾
- •Del-brax demonstrated intended biological effects with reductions in KHDC1 and creatine kinase, establishing proof-of-mechanism in a rare, progressive muscular dystrophy with high unmet need
- •Novartis is pursuing accelerated approval based on phase 1/2 biomarker data while phase 3 trial continues, potentially enabling market entry before long-term clinical efficacy data mature
- •Watch for FDA's decision on accelerated approval pathway and phase 3 efficacy readout (Week 78); competitive positioning against Sarepta's SRP-1001 will hinge on clinical outcome superiority
NovartisAvidity BiosciencesSarepta Therapeuticsdelpacibart braxlosirandel-braxSRP-1001
→ Read original articleClinical Trials•Fierce Biotech•Jun 11, 2026
Caribou boosts case that off-the-shelf CAR-T matches autologous drugs ahead of phase 3
background ▾
- •Caribou's off-the-shelf CAR-T (vispa-cel) achieves median PFS of 17.1 months, matching or exceeding autologous CAR-T standards (Breyanzi 14.8m, Yescarta 14.9m) with favorable safety profile in phase 1 data
- •Clinical strategy targets access-limited populations (medically ineligible patients, geographically remote) rather than head-to-head superiority, with phase 3 designed to include community hospital administration
- •Watch for: Phase 3 initiation and enrollment; funding announcements or partnership deals given $118.6M cash position and H2 2025 runway depletion; competitive positioning as allogeneic CAR-T landscape evolves
Caribou BiosciencesBristol Myers SquibbGilead Sciencesvispacabtagene regedleucelBreyanziYescarta
→ Read original articleClinical Trials•Fierce Pharma•Jun 12, 2026
J&J eyes rare disease expansion for blockbuster-to-be Imaavy with trial win
background ▾
- •Imaavy demonstrated efficacy in pivotal wAIHA trial, potentially enabling first-in-class approval in this rare disease with high unmet medical need
- •Label expansion could substantially broaden Imaavy's addressable market and blockbuster potential
- •Regulatory pathway and filing timeline with FDA/EMA remain to be confirmed
Johnson & JohnsonImaavypegcetacoplan
→ Read original articleClinical Trials•Fierce Pharma•Jun 12, 2026
Takeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdown
background ▾
- •Takeda's TYK2 inhibitor demonstrated superiority over Sotyktu in phase 3, validating a direct competitive threat to BMS's approved TYK2 franchise in plaque psoriasis
- •Head-to-head trial victory strengthens Takeda's market positioning ahead of anticipated launch in 2025, potentially enabling premium pricing or rapid formulary adoption
- •Monitor Takeda's regulatory filings and launch timeline, BMS's response strategy (including potential Sotyktu label optimizations), and payer coverage decisions that will determine true market capture
Takeda PharmaceuticalBristol Myers SquibbSotyktuTakeda TYK2 inhibitor (unnamed)
→ Read original articleClinical Trials•Endpoints News•Jun 11, 2026
Sensorion axes hearing loss program; Novartis' biomarker data in muscular dystrophy
background ▾
- •Sensorion is eliminating one hearing loss development program while retaining another, signaling a strategic pivot in its otology portfolio
- •Novartis has generated biomarker data in muscular dystrophy, though the therapeutic candidate, trial stage, and clinical significance remain unclear from this summary
SensorionNovartis
→ Read original article